FORT WORTH, Texas, September 29, 2026 — Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it will present new scientific research and offer a range of educational and immersive experiences at Academy 2026 (American Academy of Optometry Annual Meeting), taking place September 30–October 3 in Anaheim, California.

Alcon will share research spanning dry eye disease, contact lenses and contact lens care, including new scientific presentations related to TRYPTYR^® (acoltremon ophthalmic solution) 0.003% and the company’s broader dry eye portfolio. Attendees will also have opportunities to engage with Alcon innovations through the WaterInnovations™ Immersive Experience, MARLO demonstrations and an Innovation Suite featuring Voyager™ Direct Selective Laser Trabeculoplasty (DSLT) and the Valeda^® photobiomodulation (PBM) device.

“Academy 2026 provides an important opportunity for Alcon to advance scientific exchange around dry eye disease and deepen understanding of the patient experience,” said Lisa Praeger, General Manager, U.S. Ocular Health Pharmaceutical, Alcon. “Following the U.S. launch of TRYPTYR, our continued investment in research across our pharmaceutical and over-the-counter dry eye portfolio reflects Alcon’s commitment to supporting eye care professionals with evidence and education. We look forward to engaging with the optometric community around new research that can help inform conversations with patients and clinical practice.”

Advancing Dry Eye Science and Scientific Exchange

At Academy 2026, Alcon will present new dry eye research examining patient satisfaction, symptoms and quality of life across its pharmaceutical and over-the-counter dry eye portfolio.^2,3 The research will explore a range of patient experiences and clinical considerations, including treatment satisfaction, the impact of dry eye on daily activities and work, patient-reported symptoms and measures of tear film and meibomian gland function. ^2,3

Featured dry eye poster presentations include:

• Comparing Patient-Reported Symptoms in Perfluorohexyloctane Ophthalmic Solution and SYSTANE^® PRO Users²
• Assessing Meibomian Gland Function in Dry Eye Subjects Treated with PFHO or SYSTANE^® PRO³

Nearly one year after the U.S. commercial launch of TRYPTYR, Academy will also feature new research focused on the experiences of people with dry eye disease treated with acoltremon ophthalmic solution 0.003%, including quality of life, daily functioning and treatment satisfaction.^1,4

Featured TRYPTYR poster presentations include:

• Evaluating the Impact of Acoltremon 0.003% on a Subject’s Quality of Life and Ability to Perform Work⁴
• Understanding the Satisfaction of Symptomatic Lifitegrast Patients Who Switched to Acoltremon¹

Supporting Healthy Contact Lens Wear Through Research and Education

Alcon will also present new research across its contact lens portfolio, with scientific presentations focused on lens performance, wearer experience and the evolving needs of patients and Eye Care Professionals.^5,6 The research includes studies evaluating weekly replacement and daily disposable lenses, with a focus on factors such as vision, comfort, digital device use and patient satisfaction.^5,6

Featured contact lens presentations include:

• Performance and Safety Evaluation of Weekly Replacement Serafilcon A Compared to Biweekly Replacement Senofilcon A Silicone Hydrogel Contact Lenses⁵
• Evaluation of Wear Experience with a Weekly Replacement Toric Contact Lens in Neophyte Wearers⁶

Alcon will also host an educational luncheon focused on expanded toric parameters within the WaterInnovations portfolio, offering attendees an additional opportunity to engage with education related to contact lens fitting and patient needs.

Bringing Science and Innovation to Life at Academy

In addition to its scientific presentations, Alcon will offer educational and immersive experiences throughout Academy that give ECPs opportunities to explore new technologies, engage with Alcon experts and consider how innovations may support patient care and practice needs.

The Alcon WaterInnovations Immersive Experience will bring the science behind the portfolio to life through an interactive educational environment, giving attendees an opportunity to explore the technologies and scientific principles supporting the WaterInnovations portfolio.

The Innovation Suite will feature Voyager DSLT and Valeda PBM, giving optometrists an opportunity to learn more about technologies supporting care for patients with glaucoma and dry age-related macular degeneration (AMD).^7-10

Attendees will also be able to explore MARLO through demonstrations in the Alcon booth, along with additional professional education and meeting activities designed to help Eye Care Professionals engage with Alcon innovations and scientific programming.

For the full schedule of Alcon scientific presentations, educational programming, demonstrations and meeting activities, visit www.myalcon.com/professional/events/alcon-at-aoa.

Attendees can also visit Alcon at booth #712.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries and territories each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

Connect with us on Facebook and LinkedIn.

TRYPTYR INDICATIONS AND USAGE
TRYPTYR (acoltremon ophthalmic solution) 0.003% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).

TRYPTYR IMPORTANT SAFETY INFORMATION
Warnings and Precautions 
Potential for Eye Injury and Contamination: To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces.

Use with Contact Lenses: TRYPTYR should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of TRYPTYR.

Adverse Reactions
In clinical trials, the most common adverse reaction was instillation site pain (50%).

Please click here for the TRYPTYR Full Prescribing Information.

About Valeda PBM
Valeda PBM multiwavelength treatments are for patients suffering from dry AMD. The Food & Drug Administration (FDA) has authorized marketing of the PBM device treatment for dry AMD patients to improve vision.

About Voyager DSLT
Indications / Intended Use: The Direct Selective Laser Trabeculoplasty (DSLT) device is an ophthalmic laser device designed for performing selective laser trabeculoplasty. It is an automated device for direct selective laser trabeculoplasty (DSLT) that employs a Q‒switched, 3‒ns pulse width, frequency-doubled Nd: YAG laser of wavelength 532 nm. It directs the 400‒μm diameter laser beam to the eye limbus region without any contact with the patient's eye. An image-processing algorithm automatically locates the target area on the limbus, which the operator or Eye Care Professional (ECP) adjusts as necessary. After the operator confirms the limbus target, an eye-tracking algorithm tracks eye movement so that the laser pulses are delivered accurately to the targeted location on the limbus. Refer to the Directions for Use for the accessories/consumables and User Guide for a complete listing of indications, warnings, cautions and notes.

*Paid Alcon Consultant
 

References

1. Montaquila S., et al. Understanding the Satisfaction of Symptomatic Lifitegrast Patients Who Switched to Acoltremon. To be presented at: American Academy of Optometry Annual Meeting; September 2026; Anaheim.
2. Tichenor AA., et al. Comparing Patient-Reported Symptoms in Perfluorohexyloctane Ophthalmic Solution and SYSTANE^® PRO Users. To be presented at: American Academy of Optometry Annual Meeting; September 2026; Anaheim.
3. Pucker AD., et al. Assessing Meibomian Gland Function in Dry Eye Subjects Treated with PFHO or SYSTANE^® PRO. To be presented at: American Academy of Optometry Annual Meeting; September 2026; Anaheim.
4. Wesley G., et al. Evaluating the Impact of Acoltremon 0.003% on a Subject’s Quality of Life and Ability to Perform Work. To be presented at: American Academy of Optometry Annual Meeting; September 2026; Anaheim.
5. Bickles K., et al. Performance and Safety Evaluation of Weekly Replacement Serafilcon A Compared to Biweekly Replacement Senofilcon A Silicone Hydrogel Contact Lenses. To be presented at: American Academy of Optometry Annual Meeting; September 2026; Anaheim.
6. Fogt J., et al. Evaluation of Wear Experience with a Weekly Replacement Toric Contact Lens in Neophyte Wearers. To be presented at: American Academy of Optometry Annual Meeting; September 2026; Anaheim.
7. Brown GC, Brown MM, Sharma S, et al. The burden of age-related macular degeneration: a value-based medicine analysis. Trans Am Ophthalmol Soc. 2005;103:173-186.
8. Valeda US User Manual (LBL-0001-01 REV C) (REF-27575).
9. Alcon data on file, 2026. REF-29563.
10. Alcon data on file, 2022. REF-2479.

Media Relations

Steven Smith
+ 41 589 112 111 (Geneva)
+ 1 817 615 2666 (Fort Worth)
[email protected]